All articles

Photo by Pavel Danilyuk from Pexels

ORIC Reduces Workforce by 20% But Set To Tackle Two Late-Stage Programs In 2026

Novartis’ Win Streak With Ianalumab Continues With Solid ITP Treatment Data Release

Novartis Scores Huge Win In Sjögren’s disease With Dual Action Monoclonal Antibody Ianalumab

Bicycle Reduces 25% Of Staff Amid Second Half Of 2025 Program Updates Expected

Eli Lilly’s Stock Price Drops As Oral GLP-1 Achieves Moderate Weight Loss In Late-Stage Testing

Tern Makes Shift In Pipeline To Cancer Asset TERN-701 As Obesity Space Gets Crowded

BioMarin Gets Rid Of Palynziq Successor To Treat PKU For Lack Of Goal Being Met

Vertex’s Phase 2 Failure Leaves Next-Gen VX-993 Pain Drug On The Chopping Block

Scroll to Top